Xconomy’s Digital Events →
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA... Read more »
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.